BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenSci Regeneration Sciences Inc. Announces Change Of Name, Delisting From TSX And Listing And Trading On NEX


10/19/2005 5:10:09 PM

VANCOUVER, British Columbia, Nov. 3 /PRNewswire-FirstCall/ -- SMC Ventures Inc. ("SMC" or the "Company")(Symbol - NEX: SMV.H), previously GenSci Regeneration Sciences Inc., (TSX: GNS) ("GenSci") announces that, as a result of the completion of its plan of arrangement, and the acquisition of substantially all of its assets by IsoTis S.A., its common shares were delisted from the Toronto Stock Exchange (the "TSX") at the close of trading on October 30, 2003. The Class A common shares of SMC were listed on the NEX Board of the TSX Venture Exchange under the trading symbol SMV.H on October 31, 2003. In light of the completion of the Company's plan of arrangement, SMC now holds no significant operating assets. Its shares will continue to trade on the NEX Board until such time as a qualifying transaction is announced and completed in accordance with the policies of the TSX Venture Exchange. At this time, the Company is not involved in any discussions or negotiations with any other party relating to a qualifying transaction and there is no certainty that any discussions or negotiations will arise.

In addition, in accordance with the terms of the Company's plan of arrangement and as previously announced by GenSci on October 27, 2003, the SMC board of directors has determined that the final exchange ratio will be 0.475 of an IsoTis S.A. share for each GenSci share held at the close of trading on October 30, 2003. Accordingly, each GenSci shareholder will receive, for every 100 shares of GenSci previously held by them, 47.5 IsoTis shares and 10 SMC Class A shares. On October 27, 2003 it was announced that the exchange ratio would be a minimum of 0.46, with a final determination to be made by not later than October 31. Distribution of the IsoTis and SMC shares is expected to commence after the close of business on Monday, November 3, 2003.

IsoTis S.A. currently trades in Swiss francs on the Swiss Exchange (ISON) and in Euros on Euronext (ISON). IsoTis has received conditional approval to list the IsoTis Shares on the TSX. The listing is subject to IsoTis meeting TSX requirements, including the filing of documentation on or as soon as possible after the Effective Date. The listing on TSX will occur as soon as practicable thereafter.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For information contact: Hugh Notman President, SMC Ventures Inc. Tel: 604-689-2495 Louis G. Plourde Investor/shareholder relations Tel: (800) 561-2955 (IsoTis North America)

SMC Ventures Inc.

CONTACT: Hugh Notman, President of SMC Ventures Inc., +1-604-689-2495,or Louis G. Plourde, Investor/shareholder relations, +1-800-561-2955, ofIsoTis North America



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES